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Digital arterial pressure pulse wave analysis and
cardiovascular events in the general population:
the Prevention of Renal andVascular End-stage
Disease study
Maarten A. De Jonga, Arie M. Van Roonb, Jens T. Bakkera,b, Hendrik T.J. Bijena,b,
Douwe J. Mulderb, Frank P. Brouwersc, Wiek H. Van Gilstc, Adriaan A. Voorsc,
Ron T. Gansevoorta, Stephan J.L. Bakkera,d, and Martin H. De Borsta
Background: Arterial stiffness influences the contour of
the digital pressure pulse wave.
Method: Here, we investigated whether the digital pulse
propagation index (DPPI), based on the digital pressure
pulse wave, DPPI is associated with cardiovascular events,
heart failure, and mortality in a large population-based
cohort. Between 2001 and 2003, DPPI was measured with
a PortaPres noninvasive hemodynamic monitoring device
(FinaPres Medical Systems, Amsterdam, The Netherlands)
in participants of the Prevention of Renal and Vascular
End-stage Disease study, a community-based cohort. We
assessed the main determinants of the DPPI and
investigated associations of DPPI with cardiovascular events
and mortality.
Results: The study included 5474 individuals. Mean age
was 52.311.8 years and 50.5% was male. Median
baseline DPPI was 5.81 m/s (interquartile range 5.47–6.20).
Higher age, mean arterial blood pressure, body height,
heart rate, current smoking, and lower HDL cholesterol
levels and waist circumference were independent
determinants of the DPPI (r2¼ 0.43). After adjustment for
heart rate, highlogDPPI was associated with all-cause
mortality [hazard ratio: 1.67, 95% confidence interval
(1.55–1.81) per SD; P< 0.001], cardiovascular mortality
[hazard ratio 1.95 (1.72–2.22); P<0.001], and incident
heart failure with reduced ejection fraction [hazard ratio
1.81 (1.60–2.06); P< 0.001]. These associations remained
independent upon further adjustment for confounders.
Optimal cutoff values for DPPI ranged between 6.1 and
6.3 m/s for all endpoints. After multivariable adjustment,
DPPI was no longer associated with coronary artery disease
events or cerebrovascular events.
Conclusion: The DPPI is associated with an increased risk
of development of new onset heart failure with reduced
ejection fraction and all-cause and cardiovascular mortality,
but not with coronary artery events or cerebrovascular
events.
Keywords: heart failure, mortality, pulse contour analysis,
risk factors
Abbreviations: AUC, area under the curve; CAD,
coronary artery disease; cfPWV, carotid–femoral pulse
wave velocity; CVD, cardiovascular disease; DPPI, digital
pulse propagation index; DVP, digital volume pulse; eGFR,
estimated glomerular filtration rate; HFpEF, heart failure
with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; ICD, International Statistical
Classification of Diseases and Related Health Problems;
IQR, interquartile range; LVEF, left ventricular ejection
fraction; MAP, mean arterial pressure; PPT, pulse
propagation time; PREVEND, Prevention of Renal and




ardiovascular disease (CVD) is the leading cause of
death worldwide [1]. Large artery stiffness is a hall-
mark of vascular aging, and may be a consequence
of pathological processes including hypertension.
Increased arterial stiffness is associated with cardiovascular
risk factors, morbidity [2–4], and mortality [2,4–6]. Hence,
the early detection of arterial stiffening may contribute
to the identification of high-risk patients, and may thereby
improve prevention of CVD [7,8].
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Digital pulse wave analysis is a technique that intends to
assess arterial stiffness using the peripheral arterial pulse
waveform. This waveform can be measured from a finger,
using photoplethysmography or a pressure sensor [9–11].
Here, we obtained digital finger pressure pulse data, which
can subsequently be used to derive the pulse propagation
time (PPT), defined as the time between the systolic and
diastolic peak (Fig. 1) [9]. Finally, the digital pulse propa-
gation index (DPPI, expressed in meter per second) can be
calculated by dividing the height of each individual by the
PPT [9]. DPPI Previous studies have shown that digital
volume pulse (DVP) analysis, which is a slightly different
method based on photopletysmography, has a low failure
rate and good within-individual repeatability [12,13] and
has been correlated with individual cardiovascular risk
scores [12–14]. Digital pulse wave measurement is rela-
tively simple, rapid and requires no special training [8–10].
However, it remains unclear whether DPPI is a predictor
of cardiovascular outcomes. While pulse contour analysis
initially appeared to correspond closely with the gold
standard of arterial stiffness measurement, carotid–femoral
pulse wave velocity (cfPWV) [10,13], later studies only
observed a weak association between these methods
[15]. Although cfPWV has been clinically validated, pro-
spective data on associations between DPPI and cardiovas-
cular morbidity and mortality are sparse.
Here, we investigated potential associations between
the pulse contour-based DPPI, measured using a pressure
sensor (PortaPres), and cardiovascular outcomes in
the general population-based Prevention of Renal and
Vascular End-stage Disease (PREVEND) cohort.
METHODS
Study population
The study was performed using the data of the PREVEND
cohort study, which has been described elsewhere [16].
In summary, between 1997 and 1998, all inhabitants of the
city of Groningen, The Netherlands, aged 28–75 years
(N¼ 85 421) were asked to send in a first morning urine
sample and a short questionnaire on demographics and
CVD history. 40 856 individuals responded (47.8%). All
individuals with urinary albumin excretion (UAE) more
than 10 mg/l (N¼ 7786) in the urine sample and a randomly
selected control group with a UAE less than 10mg/l
(N¼ 3395) were invited to an outpatient clinic for a detailed
assessment of cardiovascular and renal risk factors, includ-
ing filling in questionnaires, measuring anthropometrics,
and blood and urine sampling. After excluding individuals
with insulin-dependent diabetes mellitus, pregnant
women, and individuals unable or unwilling to participate,
a total of 8592 individuals completed the screening.
Between2001 and2003, 6894 individualsof thePREVEND
study participated in a follow-up examination. At this time,
the DPPI was measured in 5487 participants using pulse
contour analysis. This subcohort was used for the present
analysis. The PREVEND study was approved by the medical
ethics committee of theUniversityMedical CenterGroningen
and abides to the principles of the Declaration of Helsinki.
Digital pulse propagation index measurement
The DPPI was measured from the middle finger for 15min
in supine position, using a Portapres finger blood pressure
(BP) monitor and Beatscope software (Finapres Medical
Systems, Amsterdam, The Netherlands). This system uses a
servo-system to continuously register the digital finger
pressure pulse [17]. We subsequently analyzed the pulse
wave to derive PPT, defined as the time between the
systolic and diastolic peak, as described by Millasseau
et al. [9]. The DPPI, expressed in meter per second, was
calculated by dividing the height of each individual by the
PPT [9]. The intra-individual coefficient of variation of DPPI
assessment over the 15min of measurement was 4.1%.
Assessment of endpoints
Data onhospitalization for nonfatal CVDwere obtained from
the Dutch national registry of hospital discharge diagnoses.
Coronary artery disease (CAD) events and cerebrovascular
events were coded according to International Statistical
Classification of Diseases and Related Health Problems
(ICD)-10. CAD events were defined as myocardial infarction,
a diagnosis of ischemic heart disease, coronary artery bypass
grafting or percutaneous transluminal coronary angioplasty.
Cerebrovascular events were defined as intracranial hemor-
rhages, occlusion and stenosis of cerebral precerebral arter-
ies, or carotid desobstruction. Both fatal and nonfatal events
were scored. New onset heart failure [with either reduced
(HFrEF, left ventricular ejection fraction (LVEF) 40%) or
preserved (HFpEF, LVEF 50%) ejection fraction]were iden-
tified by an adjudication committee in accordance with the
guidelines of the European Society of Cardiology, as pub-
lished previously [18]. Mortality data were obtained through
the municipal register. Cause of death was classified using
the primary cause of death as listed on the death certificate
using ICD-10. Person-time was calculated from the date of
DPPI measurement and the date of death. Surviving patients
were censored based on the date of the last attended follow-
up visit.
FIGURE 1 The digital pulse waveform consists of a direct pressure wave traveling
directly from the heart to the finger, and a second wave which is reflected from
the resistance arteries in the lower body. Digital pulse propagation index is calcu-
lated by dividing the height of a patient (h) by the difference in arrival time (pulse
propagation time) between this first and second wave.
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Assessment of covariates
BP was measured on the right arm, in supine position, every
minute for 10min, using an automatic Dinamap XL Model
9300 series device (Johnson-Johnson Medical, Tampa, Flor-
ida, USA). The mean of the last two recordings was used to
calculate the mean arterial BP (MAP). Participants collected
two 24-h urine samples. UAE was determined by nephe-
lometry (Dade Behring Diagnostic, Marburg, Germany).
Urine sodium excretion was measured with a MEGA clinical
chemistry analyzer (Merck, Darmstadt, Germany). Plasma
HDL and total cholesterol, triglycerides, N-terminal-pro
brain natriuretic peptide (NT-proBNP) and serum glucose
and creatinine were measured on a Roche Modular analyzer
(Roche Diagnostics, Mannheim, Germany).
Self-administered questionnaires were used to assess
demographics, cardiovascular and renal medical history
and family history, medication use, ethnicity, smoking status,
alcohol consumption, and attained education [16]. Data on
medication use was complemented with information from
community pharmacies (with complete medication records
of>90%ofparticipants) [19]. Smoking statuswas categorized
as never, former, and currently smoking. Type 2 diabetes
mellitus was defined as a fasting plasma glucose more
than 7.0mmol/l, a nonfasting plasma glucose more than
11.1mmol/l, or use of antidiabetic medication. Estimated
glomerular filtration rate (eGFR) was calculated using the
creatinine-based Chronic Kidney Disease-Epidemiology
collaboration (CKD-EPI) equation, which also includes var-
iables for age, sex, and ethnicity. Missing data on covariates
(number of cases: cholesterol: 226, NT-ProBNP: 165, eGFR:
164, waist circumference: 22, urine albumin excretion: 124)
were handled using multiple imputation.
Statistical analysis
Data are shown as mean and SD or median and interquartile
range (IQR) for skewed distributed variables. Categorical
variables are shown as total and percentage. The DPPI was
log 10-transformed for all analyses. Covariates with skewed
distributions were log-transformed when appropriate.
Differences in baseline variables across these quartiles were
assessed using analysis of variance (ANOVA), Kruskal–
Wallis, and Chi-squared tests. Univariable and subsequent
multivariable linear regression was used to assess likely
determinants of the DPPI.
Cox proportional hazards models were subsequently
used to estimate hazard ratios for the outcomes of interest
based on the logDPPI. Harrell’s C was calculated as a
measure of goodness of model fit. The initial model was
adjusted for heart rate (HR) (model 1), and subsequent
models were additionally adjusted for age, sex, and body
height (model 2), MAP, use of antihypertensive drugs,
smoking, prior history of CVD and NT-proBNP (model
3), and lastly for waist circumference, HDL cholesterol,
triglycerides, presence of diabetes mellitus, eGFR, UAE,
and urinary sodium excretion (model 4). Independent
associations between logDPPI and outcomes were subse-
quently investigated again after exclusion of participants
with a history of CVD, using the fully adjusted model
(model 4). To visualize significant associations between
the DPPI and outcomes, restricted cubic splines were
generated with knots placed at the 10th, 50th, and 90th
percentile. Receiver operating characteristic (ROC) curves
were used to identify the optimal cutoff values for DPPI
based on Youden’s J statistic (sensitivityþ specificity 1)
[20]. Multiplicative interaction terms and effect modification
was used to explore the consistency of the association
between the DPPI and mortality. The investigated potential
effect modifiers were relevant correlates of DPPI, identified
by the prior linear regression analysis, as well as clinically
relevant covariates. For this purpose, continuous variables
weredichotomizedbasedonclinically relevant cutoff values.
Statistical analyses were performed using SPSS version
23.0 (SPSS, Inc. Chicago, Illinois, USA). For all tests, a two-
sided P value of less than 0.05 was regarded as statistically
significant. Figures were generated using Graphpad version
6 (GraphPad Software, San Diego, California, USA).
Restricted cubic spline fitting was performed with R 3.2.4
(R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Mean ageof the 5487 PREVEND participants in our study was
52.3 11.8 years and 50.6% were male. The majority of the
cohort (96.1%) was of white descent. Median baseline DPPI
was 5.81m/s (IQR 5.47–6.20). The distribution of DPPI was
skewed to the right. Baseline characteristics of the cohort
per quartile of DPPI are presented in Table 1. Participants
with high DPPI were older (P< 0.001) and more likely to be
male (<0.001). In addition, high DPPI was associated
with established cardiovascular risk factors, including mean
arterial BP (MAP) and smoking (all P< 0.001).
Associations between potential determinants and logDPPI
were further explored using multivariable linear regression
analysis (Table 2). Higher age, higher MAP, greater length,
higher HR, active smoking, male sex, and lower HDL choles-
terol levels were all associated with a higher DPPI. The
resulting model explained 43% of the variance in DPPI. In
multivariablemodelsadjusted forage sexandheight, diastolic
bloodpressure (DBP)wasmore stronglyassociatedwithMAP
(b 0.342) or DBP (b 0.362) than with SBP (b 0.265), and was
only weakly associated with pulse pressure (PP) (b 0.078;
Supplemental Table 1, http://links.lww.com/HJH/B279).
Digital pulse propagation index and mortality
During a median follow-up of 8.3 (IQR 7.7–8.9) years, 289
(5.3%) participants died, of whom 74 (1.3%) of cardiovas-
cular causes. Participants who died had a higher DPPI than
those who did not (5.78 [5.46–6.62] vs. 6.30 m/s [5.83–6.78];
P< 0.001). Cox regression analysis showed a significant
association between logDPPI and the risk of both all-cause
[hazard ratio 1.67 (1.55–1.81) per SD change, P< 0.001] and
cardiovascular mortality [hazard ratio 1.95 (1.72–2.22) per
SD change, P< 0.001; Fig. 2]. Both associations remained
significant after multivariable adjustment for potential con-
founders (Table 3). In the fully adjusted model, each SD
increase in logDPPI was associated with a 14% greater risk of
all-cause mortality and with a 45% greater risk of cardio-
vascular mortality. The optimal cutoff value for DPPI in
relation to all-cause mortality was 6.2 m/s [area under the
curve (AUC)ROC: 0.70; sensitivity: 55%; specificity: 79%]. For
cardiovascular mortality, the optimal cutoff value was
6.3 m/s (AUCROC: 0.75; sensitivity: 64%; specificity: 80%).
De Jong et al.
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The association between DPPI and mortality was not mate-
rially changed when the model was adjusted for SBP rather
than MAP (Supplemental Table 2, http://links.lww.com/
HJH/B279).
The association between logDPPI and mortality was
notably modified by age, MAP, the use of antihypertensive
drugs and smoking, but not by sex (Supplemental Fig. 1,
http://links.lww.com/HJH/B279). However, effect modifi-
cation by MAP or the use of antihypertensive drugs was no
longer present when the model was adjusted for age
(Pinteraction¼ 0.74 and Pinteraction¼ 0.50, respectively). When
participants with a prior history of CVD were excluded,
DPPI remained significantly associated with all-cause and
cardiovascular mortality [fully adjusted model: hazard ratio
1.20 (1.05–1.37), P¼ 0.007 and 1.63 (1.33–1.99) per SD
increase in logDPPI, P< 0.001, respectively]. logDPPI was
not associated with noncardiovascular mortality after
adjustment for HR, age sex, and body height [hazard ratio
1.07 (0.99–1.12), P¼ 0.08].
Association of the digital pulse propagation
index with cardiovascular events
During follow-up, 272 (5.0%) participants experienced a
CAD event and 99 (1.8%) experienced a cerebrovascular
event. Results of Cox regression analysis are shown in
Table 4. logDPPI was significantly associated with both
CAD [hazard ratio per SD 1.54 (95% confidence interval
1.41–1.67), P< 0.001] and cerebrovascular events [hazard
ratio 1.63 (1.43–1.87), P< 0.001] in models adjusted for HR.
These associations remained after further adjustment for
age, sex and body height [CAD events: hazard ratio 1.17
(1.05–1.32), P¼ 0.009; cerebrovascular events: hazard ratio
1.26 (1.06–1.49) per SD, P¼ 0.0!], but lost significance upon
further adjustment for covariates.
Association of the digital pulse propagation
index with heart failure
In total, 146 participants developed new onset heart failure
during follow-up. Of these, 86 (1.6%) participants
TABLE 1. Baseline characteristics according to quartiles of digital pulse propagation index
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Full cohort <5.47 m/s 5.47–5.81 m/s 5.81–6.20 m/s >6.20 m/s P value
Participants, n 5487 1371 1372 1372 1372
DPPI (mean over 15 min) 5.81 [5.47–6.20] 5.22 [5.11–5.36] 5.64 [5.56–5.72] 5.98 [5.89–6.08] 6.55 [6.34–6.90]
Men (%) 50.6 19.8 47.9 65.2 69.8 <0.001
Age (years) 52.311.8 47.110.3 49.711.1 52.911.3 59.411.0 <0.001
Waist circumference (cm) 91.912.6 86.312.6 89.811.7 93.911.5 97.411.8 <0.001
Length (m) 1.730.09 1.680.08 1.730.09 1.760.09 1.750.09 <0.001
Race (%) <0.001
White 96.1 94.3 95.8 97.1 97.1
Black 1.0 1.0 0.8 0.6 1.4
Asian 1.9 3.3 2.2 1.0 0.9
Other 1.1 1.4 1.2 1.3 0.6
Family history of CVD (%) 48.4 45.0 48.4 50.7 49.3 <0.001
History of CVD (%) 6 3.3 4.1 6.4 10.2 <0.001
SBP (mmHg) 125.518.3 115.514.8 122.716.3 127.016.0 136.719.2 <0.001
DBP (mmHg) 73.49.1 67.07.2 71.67.5 75.17.8 79.79.0 <0.001
MAP (mmHg) 92.212.3 84.49.6 90.010.6 93.810.3 100.612.4 <0.001
Pulse pressure (mmHg) 52.213.0 48.511.2 51.112.5 52.212.2 56.914.3 <0.001
Heart rate (bpm) 68.410.0 65.08.5 67.29.5 69.39.8 72.310.6 <0.001
Use of AHD (%) 20.9 14.1 16.2 19.9 32.7 <0.001
Smoking (%) <0.001
Never 29.6 37.6 32.9 28.9 20.0
Former 41.8 39.2 40.7 41.7 47.2
Current 27.3 21.7 26.3 29.4 32.8
Alcohol use (%) <0.001
None/hardly ever 23.0 25.5 22.7 20.8 23.4
1–4/month 15.8 18.7 17.0 13.9 13.8
2–7/week 35.2 37.2 35.2 36.2 32.7
1–3/day 20.2 15.5 21.0 22.5 22.2
>3/day 5.2 2.6 4.1 6.6 7.8
Total cholesterol (mmol/l) 5.421.0 5.11.0 5.391.05 5.531.05 5.591.04 <0.001
HDL cholesterol (mmol/l) 1.22 (1.04–1.43) 1.33 (1.15–1.54) 1.25 (1.06–1.47) 1.17 (1.00–1.38) 1.14 (0.97–1.35) <0.001
Triglycerides (mmol/l) 1.10 (0.81–1.58) 0.90 (0.67–1.28) 1.06 (0.77–1.50) 1.22 (0.90–1.72) 1.30 (0.93–1.88) <0.001
Use of LLD (%) 8.9 5.9 7.1 8.6 14.1 <0.001
History of diabetes mellitus (%) 2.4 1.3 1.9 2.1 4.3 <0.001
Serum glucose (mmol/l) 4.930.92 4.720.81 4.880.91 4.940.76 5.171.10 <0.001
Serum kreatinine (mmol/l) 73.719.8 68.513.5 72.618.98 75.115.2 78.627.3 <0.001
eGFR (CKD-EPI) 93.315.8 96.514.7 95.415.3 93.714.9 87.774.5 <0.001
Urinary sodium excretion 14554 134.348.0 143.151.8 151.556.0 152.659.3 <0.001
Urinary albumin excretion 8.60 [6.06–15.1] 7.09 [5.49–10.83] 8.16 [5.95–13.3] 9.11 [6.37–14.8] 11.28 [7.06–26.92] <0.001
Data presented as mean SD, or median [IQR] or percentage of the population for normally, skewed, or nominal data, respectively. Differences were tested using analysis of variance
(ANOVA), or Kruskal–Wallis tests for continuous data and with x2 tests for categorical data. AHD, antihypertensive drugs; CKD-EPI, Chronic Kidney Disease-Epidemiology collaboration;
CVD, cardiovascular disease; DBP, diastolic blood pressure; DPPI, digital pulse propagation index; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LLD, lipid lowering
drugs; MAP, mean arterial pressure.
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developed HFrEF while 60 (1.1%) developed HFpEF.
logDPPI was associated with incident HFrEF [hazard ratio
1.81 (1.60–2.06), P< 0.001; Fig. 2] and incident HFpEF
[hazard ratio 1.31 (1.04–1.63), P¼ 0.019]. The association
between DPPI and new-onset HFrEF remained significant
in the fully adjusted model [hazard ratio 1.32 (1.08–1.60),
P¼ 0.005; Table 5], suggesting a 32% greater risk of incident
HFrEF per SD increase in logDPPI. The association with
HFpEF was lost after further adjustment for covariates. After
exclusion of participants with a prior history of CVD,
logDPPI remained associated with incident HFrEF [hazard
ratio 1.56 (1.29–1.90), P< 0.001 per SD]. For HFrEF, the
optimal cutoff value for DPPI was 6.1 m/s (AUCROC: 0.71;
sensitivity: 63%; specificity: 72%). Adjustment for SBP
instead of MAP did not significantly alter this association
(Supplemental Table 2, http://links.lww.com/HJH/B279).
DISCUSSION
Large artery stiffness is widely recognized as a risk factor
for cardiovascular and all-cause mortality [21]. Here, we
demonstrate that the DPPI, derived from the peripheral PP
waveform, is associated with a higher mortality risk in the
general population. The association between DPPI and
mortality was independent of traditional cardiovascular
risk factors. In the fully adjusted model, one SD higher
logDPPI was associated with a 15% higher risk of mortality,
while the risk of cardiovascular mortality was 43% higher
for an SD higher logDPPI. In addition, we demonstrate an
association between the DPPI and incident HFrEF, with a
31% greater risk of incident HFrEF per SD of logDPPI after
adjustment for confounders. These independent associa-
tions all remained significant after exclusion of partici-
pants with a known history of CVD. Optimal cutoff values
for DPPI were relatively consistent for all end points,
ranging between 6.1 and 6.3 m/s, which corresponds to
the cutoff between the third and fourth quartile of our
study population.
Pulse contour analysis has previously been shown to be
reproducible with minimal intraobserver variation [22,23].
TABLE 2. Univariable and multivariable determinants of log-
transformed digital pulse propagation index
Univariable Multivariable
b P value b P value
Age 0.386 <0.001 0.327 <0.001
Mean arterial blood pressure 0.482 <0.001 0.292 <0.001
Body height 0.228 <0.001 0.290 <0.001
Heart rate 0.241 <0.001 0.233 <0.001
Current smoking 0.098 <0.001 0.121 <0.001
Male sex 0.327 <0.001 0.068 <0.001
Waist circumference 0.314 <0.001 0.050 <0.001
HDL cholesterol 0.213 <0.001 0.037 0.005
Triglycerides 0.240 <0.001
24 h urinary albumin excretion 0.225 <0.001
Use of antihypertensive drugs 0.179 <0.001
eGFR (CKD-EPI) 0.157 <0.001
Total cholesterol 0.137 <0.001
24-h urinary sodium excretion 0.118 <0.001
History of cardiovascular disease 0.112 <0.001
Use of lipid-lowering drugs 0.107 <0.001
NT-proBNP 0.107 <0.001
History of diabetes 0.063 <0.001
Model 1: univariable analysis; model 2: multivariable model after stepwise backward
elimination (r2¼0.43). CKD-EPI, Chronic Kidney Disease-Epidemiology collaboration;
eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal-pro brain natriuretic
peptide.
FIGURE 2 Spline curve of the association between log digital pulse propagation
index and all-cause mortality (a), cardiovascular mortality (b), and heart failure with
reduced ejection fracture (c) after adjustment for heart rate. The gray area repre-
sents the 95% confidence interval of the hazard ratio.
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Previous cross-sectional studies have shown that the
method may have added benefit in the stratification of
CVD risk [12–14,22]. Our results extend these findings by
showing that differences in DPPI relate to the long-term risk
of mortality after adjustment for other risk factors, thus
providing prospective epidemiological validation for
this method.
In this cohort, higher DPPI was notably associated with
the presence of traditional cardiovascular risk factors at
baseline. In concordance with the pathophysiology
of arterial stiffening, age, HR, and MAP were strong
determinants of DPPI in a multivariable linear regression
model [2,24]. Of note, greater body height was also inde-
pendently associated with higher DPPI. Sex, waist circum-
ference, smoking status, plasma HDL cholesterol and
antihypertensive drug use were independently associated
with DPPI, but contributed comparatively little to the
regression model. In line with findings from the Framing-
ham Heart Study, we found no independent association
between arterial stiffness and either eGFR or albuminuria
[25]. In total, the final linear regression model explained
43% of the variance in DPPI.
TABLE 3. Associations of digital pulse propagation index with all-cause and cardiovascular mortality
Intermediate DPPI (Q3) High DPPI (Q4) LogDPPI continuous
Low DPPI (Q1þQ2) HR (95% CI) HR (95% CI) P (trend) HR (95% CI) per SD P Harrell’s C
All-cause mortality, n¼289
Model 1 1.0 (ref) 1.87 (1.57–2.24) 5.52 (4.13–7.38) <0.001 1.67 (1.55–1.81) <0.001 0.71
Model 2 1.0 (ref) 1.04 (0.75–1.7) 1.72 (1.24–2.39) <0.001 1.19 (1.07–1.33) 0.002 0.82
Model 3 1.0 (ref) 1.10 (0.77–1.59) 1.63 (1.17–2.28) 0.002 1.14 (1.02–1.27) 0.025 0.83
Model 4 1.0 (ref) 1.09 (0.77–1.61) 1.65 (1.18–2.30) 0.002 1.14 (1.02–1.28) 0.024 0.84
Cardiovascular mortality, n¼74
Model 1 1.0 (ref) 1.85 (1.25–2.75) 8.31 (4.55–15.16) <0.001 1.95 (1.72–2.22) <0.001 0.75
Model 2 1.0 (ref) 1.11 (0.74–1.66) 2.59 (1.36–4.95) 0.001 1.49 (1.27–1.76) <0.001 0.88
Model 3 1.0 (ref) 1.51 (0.67–3.37) 2.66 (1.37–5.16) 0.002 1.41 (1.19–1.68) <0.001 0.91
Model 4 1.0 (ref) 1.57 (0.70–3.54) 2.60 (1.33–5.08) 0.004 1.45 (1.22–1.73) <0.001 0.92
CI, confidence interval; DPPI, digital pulse propagation index; HR, hazard ratio.
TABLE 4. Associations of digital pulse propagation index with fatal and nonfatal cardiovascular events
Intermediate DPPI (Q3) High DPPI (Q4) LogDPPI continuous
Low DPPI (Q1þQ2) HR (95% CI) HR (95% CI) P (trend) HR (95% CI) per SD P Harrell’s C
CAD events, n¼227
Model 1 1.0 (ref) 2.03 (1.71–2.41) 4.43 (3.28–5.96) <0.001 1.53 (1.41–1.67) <0.001 0.68
Model 2 1.0 (ref) 1.29 (0.97–1.74) 1.93 (1.37–2.72) <0.001 1.17 (1.05–1.32) 0.009 0.76
Model 3 1.0 (ref) 1.32 (0.92–1.91) 1.54 (1.06–2.25) 0.03 1.02 (0.90–1.17) 0.74 0.81
Model 4 1.0 (ref) 1.28 (0.88–1.85) 1.50 (1.03–2.18) 0.04 1.02 (0.89–1.16) 0.78 0.81
Cerebrovascular events, n¼99
Model 1 1.0 (ref) 3.01 (2.29–3.96) 4.62 (2.76–7.74) <0.001 1.63 (1.43–1.87) <0.001 0.67
Model 2 1.0 (ref) 1.99 (1.49–2.66) 1.90 (1.07–3.36) 0.05 1.26 (1.06–1.49) 0.01 0.80
Model 3 1.0 (ref) 2.11 (1.14–3.54) 1.54 (0.86–2.76) 0.25 1.15 (0.96–1.38) 0.12 0.81
Model 4 1.0 (ref) 2.09 (1.18–3.69) 1.57 (0.87–2.83) 0.24 1.18 (0.98–1.43) 0.08 0.83
Model 1: association for log-transformed DPPI, adjusted for heart rate DPPI; model 2: model 1þ adjustment for age, sex, and body height; model 3: model 2þ adjustment for MAP, use
of antihypertensive drugs, smoking, prior history of cardiovascular disease, and NT-proBNP; model 4: model 3þ adjustment for waist circumference, HDL cholesterol, triglycerides, history
of diabetes, eGFR, urinary albumin excretion and urinary sodium excretion. CAD, coronary artery disease; CI, confidence interval; DPPI, digital pulse propagation index; eGFR, estimated
glomerular filtration rate; HR, hazard ratio; MAP, mean arterial pressure.
TABLE 5. Associations of digital pulse propagation index with new-onset heart failure
Intermediate DPPI (Q3) High DPPI (Q4) LogDPPI continuous
Low DPPI (Q1þQ2) HR (95% CI) HR (95% CI) P (trend) HR (95% CI) per SD P Harrell’s C
HFrEF, n¼86
Model 1 1.0 (ref) 2.13 (1.51–3.01) 7.32 (4.15–12.94) <0.001 1.81 (1.60–2.06) <0.001 0.74
Model 2 1.0 (ref) 1.27 (0.89–1.81) 2.64 (1.43–4.87) 0.001 1.42 (1.20–1.68) <0.001 0.83
Model 3 1.0 (ref) 1.33 (0.67–2.69) 2.16 (1.14–4.09) 0.013 1.29 (1.06–1.57) 0.010 0.89
Model 4 1.0 (ref) 1.34 (0.66–2.72) 2.26 (1.18–4.33) 0.009 1.32 (1.08–1.60) 0.005 0.91
HFpEF, n¼60
Model 1 1.0 (ref) 1.03 (0.53–2.02) 1.84 (1.02–3.35) 0.06 1.31 (1.04–1.63) 0.019 0.59
Model 2 1.0 (ref) 0.79 (0.39–1.60) 0.90 (0.46–1.76) 0.76 0.98 (0.76–1.27) 0.89 0.82
Model 3 1.0 (ref) 0.80 (0.40–1.62) 0.81 (0.41–1.59) 0.55 0.91 (0.71–1.19) 0.51 0.85
Model 4 1.0 (ref) 0.86 (0.42–1.72) 0.84 (0.42–1.66) 0.61 0.94 (0.73–1.22) 0.65 0.86
Model 1: association for log-transformed DPPI, adjusted for heart rate; model 2: model 1þ adjustment for age, sex, and body height; model 3: model 2þ adjustment for MAP, use of
antihypertensive drugs, smoking, prior history of cardiovascular disease, and NT-proBNP; model 4: model 3þ adjustment for waist circumference, HDL cholesterol, triglycerides, history of
diabetes, eGFR, urinary albumin excretion, and urinary sodium excretion. CI, confidence interval; DPPI, digital pulse propagation index; eGFR, estimated glomerular filtration rate; HFrEF,
heart failure with reduced ejection fracture; HR, hazard ratio; MAP, mean arterial pressure; NT-proBNP, N-terminal-pro brain natriuretic peptide.
Digital pulse propagation index and cardiovascular events
Journal of Hypertension www.jhypertension.com 1069
Our results show that the DPPI is independently associ-
ated with mortality, and suggest that this association is
driven by cardiovascular mortality. The DPPI was also
strongly associated with HFrEF. However, the associations
with cerebrovascular events and HFpEF were lost upon
multivariable adjustment. When analyzed as a continuous
variable, CAD was also not associated with DPPI after
adjustment for confounders. However, we did observe a
significantly higher hazard ratio for CAD for participants in
the highest quartile of our cohort. The lack of a strong
association with CAD is in line with a previous study
showing that the DPPI is not associated with CAD identified
by coronary angiography [13]. These observations may
result from the fact that the DPPI is related to peripheral
rather than aortic stiffness, unlike cfPWV [13]. Similarly,
cerebrovascular events are more strongly associated with
aortic stiffness than with peripheral arterial stiffness [26].
The significant association between cardiovascular mortal-
ity and DPPI but not (in continuous analysis) with coronary
artery events or cerebrovascular events may suggest that the
excess mortality risk in participants with high DPPI is
mainly driven by deaths due to heart failure, although this
could not be definitively clarified by our current data.
Several mechanisms have previously been proposed to
explain the associations between arterial stiffness and mor-
tality. For example, higher DPPI may be indicative of
genetic and structural predisposition to cardiovascular risk
[27]. In addition, associations have been reported between
DPPI and markers of higher bone resorption and lower
bone formation in patients with CKD stage 1–4, suggesting
a link between the DPPI and vascular calcification [28].
Lastly, arterial stiffness may be linked to systemic inflam-
mation [29–31]. Quantification of these and other processes
impacting arterial ageing is likely to aid in the prediction of
cardiovascular risk, as well as in the epidemiological and
mechanistic study of CVD. Our study has a number of
limitations. First, our study is observational in nature and
therefore no conclusions can be drawn on causality. Sec-
ond, by design, the study cohort includes a larger propor-
tion of individuals with microalbuminuria than the general
population [16]. Accordingly, we have adjusted our analy-
ses for albuminuria. Third, our cohort consists primarily of
whites due to the geographical area of recruitment; future
studies on the role of the DPPI in nonwhite populations are
warranted. Fourth, our study made use of a single 15-min
arterial stiffness measurement at baseline even though
arterial stiffening is a dynamic process, the rate of which
may vary over time. In the absence of repeated measure-
ments, this variability is unaccounted for, which may lead to
underestimation of the strength of associations due to
regression dilution bias. Fifth, the method used to derive
stiffness from the digital pressure pulse is indirect. As such,
the DPPI may not reflect true large artery stiffness due to
confounding by properties of peripheral vessels. Sixth,
cause of death in this cohort was classified using the
primary cause of death as reported on patients’ death
certificate. However, the reported cause of death may
not properly reflect the true cause of death for all patients.
On the contrary, informed consent for this study did not
allow for a full review of medical records to further clarify
cause of death. Lastly, the use of patient height to calculate
an index expressed in meters per second is relatively
imprecise, and might contribute to imprecision in the DPPI.
This is reflected by the finding that height remained a
determinant of the DPPI in linear regression analysis. How-
ever, inclusion of height in our survival analysis did not
materially alter our results. Lastly, in this study, pulse
contour analysis was performed using the digital arterial
pressure waveform. This methodology is different from
DVP, which has been used in several previous studies
[10,11]. Although these different waveforms may be relat-
able to each other through a generalized transfer function,
they are not identical and may convey different informa-
tion. To our knowledge, arterial pressure-based waveform
analysis has not been correlated with cfPWV, the current
standard to quantify arterial stiffness.
In conclusion, higher DPPI corresponded closely with
the presence of known causal risk factors for CVD in this
large, well characterized general population-based cohort.
Moreover, DPPI was independently associated with inci-
dent systolic heart failure, all-cause and cardiovascular
mortality after adjustment for these risk factors. However,
DPPI was not independently associated with risk of CAD
events or cerebrovascular events. Further validation studies
should confirm whether this accessible marker of arterial
stiffness has value in risk stratification for these end points,
and should define the position of DPPI in comparison with
other available methods to determine vascular stiffness.
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